Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease

BACKGROUND: Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still's disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case serie...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Antonio, Berlengiero, Virginia, Sota, Jurgen, Ciarcia, Luisa, Ricco, Nicola, Barneschi, Sara, Mourabi, Mariam, Lopalco, Giuseppe, Marzo, Chiara, Bellisai, Francesca, Iannone, Florenzo, Frediani, Bruno, Cantarini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584965/
https://www.ncbi.nlm.nih.gov/pubmed/33122969
http://dx.doi.org/10.1155/2020/8054961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584965/
https://www.ncbi.nlm.nih.gov/pubmed/33122969
http://dx.doi.org/10.1155/2020/8054961

Ejemplares similares